Last reviewed · How we verify
Cardiopeptidin
Cardiopeptidin is a Small molecule drug developed by Nanfang Hospital, Southern Medical University. It is currently FDA-approved.
Cardiopeptidin is being studied in a clinical trial for its potential to reduce myocardial injury in ICU patients with non-organic heart disease. The study is comparing the effects of Cardiopeptidin to a normal saline intravenous infusion.
At a glance
| Generic name | Cardiopeptidin |
|---|---|
| Sponsor | Nanfang Hospital, Southern Medical University |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cardiopeptidin CI brief — competitive landscape report
- Cardiopeptidin updates RSS · CI watch RSS
- Nanfang Hospital, Southern Medical University portfolio CI
Frequently asked questions about Cardiopeptidin
What is Cardiopeptidin?
Who makes Cardiopeptidin?
What development phase is Cardiopeptidin in?
Related
- Manufacturer: Nanfang Hospital, Southern Medical University — full pipeline
- Therapeutic area: All drugs in Cardiovascular
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing